GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug

Recent Posts

GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))
GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson’s Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada